ロード中...
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long‐term pharmacovigilance is unknown. This analysis summarises safety data collected from spontaneous a...
保存先:
| 出版年: | Br J Haematol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6594003/ https://ncbi.nlm.nih.gov/pubmed/30768680 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15790 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|